Back to Search Start Over

Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients.

Authors :
Quagliariello, Vincenzo
Canale, Maria Laura
Bisceglia, Irma
Iovine, Martina
Giordano, Vienna
Giacobbe, Ilaria
Scherillo, Marino
Gabrielli, Domenico
Maurea, Carlo
Barbato, Matteo
Inno, Alessandro
Berretta, Massimiliano
Tedeschi, Andrea
Oliva, Stefano
Greco, Alessandra
Maurea, Nicola
Source :
International Journal of Molecular Sciences; Oct2024, Vol. 25 Issue 20, p11299, 16p
Publication Year :
2024

Abstract

Cancer patients, especially long cancer survivors, are exposed to several cardio-metabolic diseases, including diabetes, heart failure, and atherosclerosis, which increase their risk of cardiovascular mortality. Therapy with glucagon-like peptide 1 (GLP1) receptor agonists demonstrated several beneficial cardiovascular effects, including atherosclerosis and heart failure prevention. Cardiovascular outcome trials (CVOTs) suggest that GLP-1 RA could exert cardiorenal benefits and systemic anti-inflammatory effects in patients with type-2 diabetes through the activation of cAMP and PI3K/AkT pathways and the inhibition of NLRP-3 and MyD88. In this narrative review, we highlight the biochemical properties of GLP-1 RA through a deep analysis of the clinical and preclinical evidence of the primary prevention of cardiomyopathies. The overall picture of this review encourages the study of GLP-1 RA in cancer patients with type-2 diabetes, as a potential primary prevention strategy against heart failure and atherosclerosis. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
16616596
Volume :
25
Issue :
20
Database :
Complementary Index
Journal :
International Journal of Molecular Sciences
Publication Type :
Academic Journal
Accession number :
180487527
Full Text :
https://doi.org/10.3390/ijms252011299